Data Sheet 2_Combination therapy with toripalimab and lenvatinib in metastatic type 2 papillary renal cell carcinoma: a Case Report.zip

BackgroundType 2 papillary renal cell carcinoma (PRCC) is an aggressive subtype of renal cell carcinoma with a poor prognosis. Diagnosis is challenging, particularly when presenting as a metastatic lung mass. This report describes a case of metastatic type 2 PRCC treated with first-line toripalimab (anti-PD-1) and lenvatinib (multikinase inhibitor), highlighting sustained clinical benefit.
Case presentationA 73-year-old man presented with cough, hemoptysis, and a large left lung mass initially misdiagnosed as primary lung cancer. Multidisciplinary re-evaluation, including immunohistochemistry (PAX8+, P504s+, also known as AMACR), confirmed metastatic type 2 PRCC. After 11 months of toripalimab (flat dose of 240 mg every 3 weeks) and lenvatinib (flat dose of 8 mg daily), serial imaging demonstrated partial response (PR) with regression of pulmonary metastases, lymphadenopathy, and obstructive pneumonia. No serious adverse events occurred.
ConclusionsThis case underscores the potential efficacy and tolerability of toripalimab-lenvatinib combination therapy in metastatic type 2 PRCC. Further clinical trials are warranted to validate this approach.

背景：2型乳头状肾细胞癌（papillary renal cell carcinoma, PRCC）是肾细胞癌的侵袭性亚型，预后不良。该疾病的诊断颇具挑战，尤其当病灶表现为转移性肺部肿块时。本病例报告介绍了1例接受一线特瑞普利单抗（toripalimab，抗PD-1单抗）联合仑伐替尼（lenvatinib，多激酶抑制剂）治疗的转移性2型乳头状肾细胞癌病例，凸显了该方案持续的临床获益。

病例报告：患者为73岁男性，因咳嗽、咯血及左侧肺部巨大肿块就诊，初始被误诊为原发性肺癌。经多学科联合重新评估，包括免疫组化检测（PAX8阳性、P504s阳性，即AMACR），最终确诊为转移性2型乳头状肾细胞癌。患者接受11个月的特瑞普利单抗（固定剂量240mg，每3周1次）联合仑伐替尼（固定剂量8mg，每日1次）治疗后，系列影像学检查显示部分缓解（PR），肺部转移灶、淋巴结肿大及阻塞性肺炎均出现消退，未发生严重不良事件。

结论：本病例凸显了特瑞普利单抗-仑伐替尼联合疗法在转移性2型乳头状肾细胞癌中的潜在疗效与耐受性，亟需开展进一步的临床试验以验证该治疗方案。